1-2 of 2
Jakob Lindberg, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Free
Paul G Richardson, MD, Sara Bringhen, MD, Peter M. Voorhees, MD, Torben Plesner, MD, Claudia Paba-Prada, MD, Ulf-Henrik Mellqvist, MD, Jeffrey A Zonder, MD, Brandi Reeves, MD, Antonio Palumbo, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Eva Nordstrom, MSc, MBA, Hanan Zubair, MSc, Jakob Lindberg, MD PhD, Pieter Sonneveld, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3150.
https://doi.org/10.1182/blood.V130.Suppl_1.3150.3150
Published: 2017
Journal Articles

Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy

Free
Maria-Victoria Mateos, MD, Joan Bladé, MD PhD, Alessandra Larocca, Albert Oriol, MD, Paula Rodriguez, MD, Adrián Alegre, MD, Michele Cavo, MD, Jan S Moreb, MD, Agne Paner, MD, Nashat Gabrail, MD, Kathleen G. Halka, MD, Hani Hassoun, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Jeffrey A Zonder, MD, Enrique M Ocio, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Sara Thuresson, MSc, Eva Nordstrom, MSc, MBA, Jakob Lindberg, MD PhD, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1841.
https://doi.org/10.1182/blood.V130.Suppl_1.1841.1841
Published: 2017